Datacentrex (DTCX) delays 2025 10-K; acquired Dogehash on Dec 15, 2025

Datacentrex (DTCX) has filed a Form NT 10-K, notifying the SEC that it will delay filing its Annual Report for the year ended December 31, 2025, due to needing more time to complete its audit. The company expects to file within the 15-day extension period allowed by Rule 12b-25. The filing also discloses that Datacentrex acquired Dogehash Technologies, Inc. on December 15, 2025, with Dogehash being treated as the accounting acquirer, which will impact the comparability of pre-acquisition financial results.

Original reporting
Published Apr 1, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 1, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$DTCX
Neutral
medium confidence
Mentioned
$DTCX
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$DTCXNeutralLow
01

Why it matters

The delayed 10-K filing suggests possible internal audit issues or strategic delays, which could temporarily unsettle investors. The acquisition indicates growth ambitions but also introduces integration risks.

02

Market read

The news has limited immediate impact on the broader market but is relevant for investors in DTCX and related sectors.

03

What to watch

The company's overall financial health and market position could mitigate the impact of the filing delay; further details are needed to assess long-term effects.

Relevance 6/10Timing: short-term (within days to weeks)

Background

Datacentrex (DTCX) is a technology company involved in data center services, recently engaged in an acquisition of Dogehash Technologies, Inc.

Company-level read

Ticker impact

$DTCXNeutralMedium confidence
Context

The news directly pertains to Datacentrex (DTCX), including its delayed 10-K filing and recent acquisition.

Expected impact

Minimal immediate price movement; potential short-term decline followed by stabilization as investors digest the news.

Evidence & confidence

The delayed filing is a common occurrence and may not significantly impact stock price unless accompanied by further negative developments. The acquisition's impact depends on integration success, which is uncertain at this stage.

Market effects

Potential caution in the technology and financial sectors due to delayed disclosures and M&A activities.

Limited, as the news pertains primarily to a US-based company.

Low; the event is company-specific without immediate global implications.

Counterpoint

The acquisition may be viewed positively as a strategic move, potentially outweighing concerns about the delayed filing.

Key entities

  • Datacentrex (DTCX)

    A data center services provider.

  • Dogehash Technologies, Inc.

    A blockchain and cryptocurrency technology firm acquired by DTCX.

Related articles

$DTCXMed

Datacentrex Reports Third Quarter 2026 Results and $30 Million Investment in Eagle LNG

Datacentrex, Inc. (DTCX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Datacentrex Reports Third Quarter 2026 Results and $30 Million Investment in Eagle LNG Eagle LNG’s established customer base and space propulsion capabilities create additional growth opportunities heading into 2027 ● Reports positive third-quarter Adjusted EBITDA of

$DTCXMed

Datacentrex Reports Second Quarter 2026 Financial Results

Datacentrex, Inc. (DTCX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Datacentrex Reports Second Quarter 2026 Financial Results; Ends Quarter with $51.9 Million in Cash and No Debt ● Revenue of $1.9 million and positive gross profit despite higher power costs and challenging digital asset market conditions ● GAAP net loss of $5.5 milli

$PALIMedAI 8/10

Palisade Bio doses first patient in ulcerative colitis trial

Palisade Bio (NASDAQ:PALI) dosed the first patient in its Phase 2b ASCENTRA-UC trial for ulcerative colitis. The company reported a Q3 2026 net loss of $14.6M, up from $2.9M in 2025. It has $113.6M in cash. The trial will enroll 204 patients, with results expected in Q4 2027. The company also plans a Phase 2a Crohn’s disease study, with enrollment starting in Q1 2027.

$IRMMed

Jefferies raises Iron Mountain stock price target on data center growth

Jefferies raised its price target on Iron Mountain (IRM) to $137 from $135, citing data center growth as a key driver. The stock is currently at $110.78, down 5% in a week but up 36.7% year-to-date. Jefferies projects data centers will contribute 20% of revenue by 2029, supporting 10% annual AFFO growth. Iron Mountain reported Q3 2026 earnings of $0.64 per share, beating estimates, with revenue up 13% year-over-year.

$NHPMedAI 9/10

NATIONAL HEALTHCARE PROPERTIES, INC. AND SUBSIDIARIES Unaudited Pro Forma Condensed Combined Financial Information

National Healthcare Properties, Inc. (NHP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 NATIONAL HEALTHCARE PROPERTIES, INC. AND SUBSIDIARIES Unaudited Pro Forma Condensed Combined Financial Information ( in thousands ) National Healthcare Properties, Inc. (including, as by context, National Healthcare Properties Operating Partnership, L.P. (the “OP”) a